Welcome to Stem Cell Congress 2020

Theme : New models, diagnostics and therapies to improve human health

CPG Scientific Events organizing the Stem Cell Congress 2020 which is going to be held from June 01-02, 2020 in Stockholm, Sweden focusing on current and future advancements in Stem Cell Research. The theme of this year's meeting is "New models, diagnostics and therapies to improve human health", which will provide an international platform for discussion and sharing of novel ideas for present and future expansions in various fields of Cell Therapies. World-leading health practitioners, clinicians, educators and researchers will present cutting-edge and practical clinical techniques based upon widely accepted evidence and will introduce new and innovative research.

We cordially invite all of you to participate in Stem Cell Congress 2020!

Why to Attend ?

World Congress on Stem Cell Research is a unique forum to bring together worldwide distinguished academics in the field of Cell and Stem Cell Research, public health professionals, scientists, academic scientists, industry researchers, scholars to exchange about state of the art research and technologies. Aim of this conference is stimulate new ideas for treatment that will be beneficial across the spectrum of Cell Research.

  • Gathering of world class researchers and budding talent from across the globe.
  • Showcase your research and get world recognition.
  • Avail chances to interact with world renowned scientists.
  • Perfectly designed schedule: Workshop, Expo areas, Cell Therapies sessions and many more. Platform to network with fellow primary care clinicians.
  • Educational workshops on diagnosis and treatment of Stem Cell Research.

Keynote Speakers @ Stemcell Congress 2020

Joel Isaias Osorio Garcia
CEO, RegenerAge Clinic

Title: The use of Bioquantine and allogeneic Mesenchymal Stem Cells combined with a spinal cord stimulation system in a No Option patient with ASIA-A scale.

Dr. Osorio is an innovative businessman with a distinct entrepreneurial mindset concentrated in adding value on the areas of Biotechnology (mRNA), Reprogramming & Regenerative Medicine for translational use in humans and a variety of clinical applications aimed for both the private and the public health sectors. He is the CEO of RegenerAge Clinic and RegenerAge Life Initiatives. VP and Clinical Developer for Bioquark,Inc. CCO at Reanima Advance Biosciences Project. President at Dr. Jois an anti-aging, beauty and cosmetic products endorsement company. VP and Chairman of the WAMS Americas Division. Earned MD degree at Westhill University. Diplomate in aesthetic medicine (UAG), Advance Fellow by the ABAARM, visiting scholar at UNC at Chapel Hill in Dermatology.

Alex Kharazi
Chief Technology Officer, Stemedica Cell Technologies, USA

Title: Human neural stem cells for the treatment of spinal cord injury

Dr. Kharazi is a physician by training. He finished Medical School in 1978 in Kiev, Ukraine, where he earned his medical degree in internal medicine and pathology. From 1978 to 1981, he was a post-doctoral fellow at the Kiev Institute of Gerontology. Dr. Kharazi received extensive training in cell biology and immunology, including tissue culture and subsequently earned his PhD in immunology. He studied age-related pathological changes of the immune system in mice and humans and his research interests included the possibility of restoring immunity in aged mice using stem cells from young adult mice. Dr. Kharazi was one of the first to discover the inhibitory effects of old thymus in mice and later published on this subject.

Richard K Burt
Professor of Medicine,
Northwestern University, USA

Title: TBA

Dr. Richard K Burt Chief of Immunotherapy and Autoimmune Diseases in the Department of Medicine, Professor of Medicine (Immunotherapy and Autoimmune Diseases). The Division of Immunotherapy and Autoimmune Diseases (DIAD) is the only center in the world devoted to a unique area of treatment and research utilizing stem cell transplantation in clinical trials for autoimmune diseases and vascular diseases. DIAD pioneered and performed America's first hematopoietic stem cell transplants to treat: Multiple Sclerosis (MS), Diabetes, Lupus, Crohn's, Rheumatoid Arthritis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Phemphigus, Dermatomyositis, Devic's, Myasthenia Gravis, Polymositis and Scleroderma.

Cheng Wang
Professor of Medicine, National Center for Toxicological Research, USA

Title: Protective effects of xenon on propofol-induced damage in human embryonic neural stem cell-derived neurons (A mechanistic study)

Dr. Cheng Wang is a Senior Research Neurobiologist at the National Center for Toxicological Research (NCTR)/US Food and Drug Administration (FDA). In 1996, Dr. Wang joined the University of Texas Medical Branch (UTMB), as a Postdoctoral Fellow in the Department of Pharmacology & Toxicology. In 2000 and 2002, he accepted appointments as Assistant Professor in the UTMB Departments of Psychiatry and Pharmacology & Toxicology, respectively. Dr. Wang joined the Division of Neurotoxicology at the NCTR in 2003. He is also an Adjunct Faculty member in the Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences (UAMS). Dr. Wang has authored or co-authored over 110 peer-reviewed scientific articles and book chapters in the areas of pharmacology, toxicology and neuroscience.

Organizing Committee

Cheng Wang
National Center for Toxicological Research, USA

Anna Burdzinska
Medical University of Warsaw

Intesar AL Ramahi
Ibn Sina Research Center

Richard K Burt
Northwestern University

Joel I. Osorio
RegenerAge Philadelphia

Borje S. Andersson
Anderson Cancer Center

Ahmed El-Hashash
Zhejiang International Campus

Yibing Li
Center for Pain Management & Rehabilitation, USA